Allogene Therapeutics Company
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing.
Investors
Funding Status:
IPO
Headquarters:
United States
Founded Date:
01.01.2017
Technology:
Сancer Diagnostics
Estimated Revenue:
$1M to $10M
Industry:
Genomic and Epigenominc Instabillity